People

Team Consulting has hired David Harris, inventor of the Conix dry powder inhaler, which was licensed to 3M Drug Delivery Systems in 2008 by his then employer, Cambridge Consultants. In 2009, Harris joined Sagentia, where… Read more . . .

MAP Pharmaceuticals has hired Frederick H. Graff as VP, Commercial Operations, a position newly created in anticipation of a potential launch of the company’s Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine. Graff was… Read more . . .

Jim Nightingale has been promoted from Senior VP for Business Development and Strategic Alliances to President of drug development company Bend Research. Rod Ray is stepping down as President but will remain as CEO and… Read more . . .

Inhaled antibiotic developer Insmed has hired Andrea (“Andi”) Holtzman Drucker as its Senior Vice President, General Counsel and Corporate Secretary, which is a newly-created position reporting directly to Insmed President and CEO Timothy Whitten. Drucker… Read more . . .

Pulmatrix, which recently launched its new iSperse dry powder delivery system, has announced the promotion of Robert Clarke to Chief Scientific Officer (CSO) and VP of Research and Development. In addition, the company has added… Read more . . .

Canadian biotech company Asmacure has announced that Martin Driscoll will replace Luc Vachon as Chief Executive Officer. Vachon is leaving the company “to pursue other business ventures.” Asmacure is developing an inhaled nictonic receptor agonist,… Read more . . .

Activaero has hired Christian Pangratz as its new Chief Business Officer, replacing Henrik Luessen. Pangratz comes to Activaero from Nektar, where he served as Executive Director of Business Development. Luessen will continue to work with… Read more . . .

Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in… Read more . . .

Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine… Read more . . .